中性粒细胞活化标志物与类风湿关节炎对JAK1/2抑制剂巴瑞替尼治疗反应的关系
该研究在271例类风湿关节炎(RA)患者和39例健康对照中检测血浆中性粒细胞活化标志物,并在接受安慰剂及2 mg、4 mg巴瑞替尼治疗的患者中于基线、12周和24周复查,同时分析多项随机试验共1651例全血RNA。结果显示巴瑞替尼可降低可溶性钙卫蛋白水平,尤其见于达到ACR20缓解的患者;基线中性粒细胞活化评分可预测巴瑞替尼治疗反应,而C反应蛋白水平不能区分应答者与非应答者。
要点
- RA患者基线血浆中性粒细胞标志物水平高于健康对照(P < 0.001)。
- 巴瑞替尼降低12周和24周可溶性钙卫蛋白水平,尤其在达到ACR20缓解的患者中。
- 基线中性粒细胞活化评分可预测巴瑞替尼治疗反应,C反应蛋白不能区分应答者与非应答者。
核心结论
- 中性粒细胞活化标志物可能为预测巴瑞替尼及其他靶向RA药物的治疗反应增加临床价值。
- 该研究支持基于免疫表型而不仅基于症状的RA个体化治疗。
研究设计与样本
- 在271例RA患者和39例健康对照中,用酶联免疫吸附试验分析血浆中性粒细胞活化标志物、钙卫蛋白和中性粒细胞胞外诱捕网(NETs)。
- RA患者在基线和接受安慰剂及2 mg、4 mg巴瑞替尼后12周和24周检测中性粒细胞活化标志物。
- 对多项随机巴瑞替尼RA试验的全血RNA进行分析,研究中性粒细胞相关转录本(n = 1,651)。
主要发现
- RA患者基线血浆中性粒细胞标志物水平高于健康对照(P < 0.001)。
- 接受巴瑞替尼降低12周和24周可溶性钙卫蛋白水平,尤其在按美国风湿病学会20%改善标准判定的治疗应答RA患者中。
- 全血RNA分析显示,在涉及不同疾病修饰治疗阶段患者的三项随机临床试验中,接受巴瑞替尼后主要中性粒细胞标志物钙卫蛋白和Fcα受体I出现相似变化。
- 血浆活化标志物聚类分析显示,基线钙卫蛋白和NETs水平升高(如中性粒细胞活化评分)可预测巴瑞替尼治疗反应。
- C反应蛋白水平不能区分应答者与非应答者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Neutrophils play an important role in regulating immune and inflammatory responses in patients with rheumatoid arthritis (RA). We assessed whether baricitinib, a JAK1/JAK2 inhibitor, could reduce neutrophil activation and whether a neutrophil activation score could predict treatment response. METHODS: Markers of neutrophil activation, calprotectin, and neutrophil extracellular traps (NETs) were analyzed using enzyme-linked immunosorbent assay in plasma from patients with RA (n = 271) and healthy controls (n = 39). For patients with RA, neutrophil activation markers were measured at baseline, 12 weeks, and 24 weeks after receiving placebo and 2 and 4 mg baricitinib. Whole-blood RNA analyses from multiple randomized baricitinib RA trials were performed to study neutrophil-related transcripts (n = 1,651). RESULTS: Baseline levels of plasma neutrophil markers were elevated in patients with RA compared to healthy controls (P < 0.001). Receiving baricitinib reduced levels of soluble calprotectin at 12 and 24 weeks, especially in patients with RA responding to treatment, as determined by American College of Rheumatology 20% improvement criteria. Whole-blood RNA analysis revealed similar changes in the predominant neutrophil markers calprotectin and Fcα receptor I upon reception of baricitinib in three randomized clinical trials involving patients with at various stages of disease-modifying therapy. Clustering analysis of plasma activation markers showed elevated levels of calprotectin and NETs (eg, a neutrophil activation score, at baseline, could predict treatment response to baricitinib). In contrast, C-reactive protein levels could not distinguish between responders and nonresponders. CONCLUSION: Neutrophil activation markers may add clinical value in predicting treatment response to baricitinib and other drugs targeting RA. This study supports personalized medicine in treating patients with RA, not only based on symptoms but also based on immunophenotyping.
引用
- Kuley R, Duvvuri B, Hasnain S, et al. Neutrophil Activation Markers and Rheumatoid Arthritis Treatment Response to the JAK1/2 Inhibitor Baricitinib. Arthritis Rheumatol. 2024. PMID: 39431356. doi:10.1002/art.43042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。